Teleflex Delivers COMPLETE Confidence with the New Arrow® ErgoPack® Complete CVC System
27 October 2020 - 9:30PM
Teleflex Incorporated (NYSE: TFX) delivers COMPLETE confidence to
central line inserters with the release of the Arrow® ErgoPack®
Complete CVC System, the most important update to its
market-leading1 portfolio of Centrally-Inserted Central Catheters
in more than a decade.
Teleflex conducted extensive research with industry-leading
vascular access professionals to select the enhancements in the new
ErgoPack® Complete System. Clinician-inspired updates to the kit
include:
- The Arrow GlideWheel™ Advancer, which provides tactile feedback
and finer control
- Nitinol Guidewire, which is kink-resistant compared to
stainless steel
- Transducer Cover to support guidelines for ultrasound use
- Pre-filled sterile saline syringes, one per catheter lumen
- Extra ChloraPrep® Skin Prep in each kit (two total)
“The ErgoPack® Complete System is built with the inserter in
mind, first and foremost,” said Jake Newman, President and General
Manager, Teleflex Vascular. “The ErgoPack® Complete System is a
powerful tool in the fight against CLABSI.1”
These new additions enhance the already-considerable power of
the market-leading2 ErgoPack® System, which features, at its heart,
Teleflex’s Arrowg+ard Blue Plus® CVC. It’s the only full-spectrum
antimicrobial CVC that protects against gram-positive,
gram-negative bacteria and fungi, the key infectious pathogens
responsible for CLABSI.
CLABSI is responsible for as many as 28,000 deaths per year in
the US.3
The ErgoPack® Complete System’s unique combination of CVC
insertion components, packaged in an ergonomic and efficient top
down, left to right configuration, helps central line inserters
comply with critical third party independent guidelines for
reducing CLABSI, including:
- Centers for Disease Control and Prevention (CDC) Category 1A
& 1B recommendations4
- Society for Hospital Epidemiology of America (SHEA)
Guidelines5
- Infusion Nursing Society (INS) Standards of Practice6
- Occupational Health and Safety Administration (OSHA) Bloodborne
Pathogens Standard7
The ErgoPack® Complete System is available in two different
configurations, in a variety of catheter French sizes.
Learn more at http://go.teleflex.com/CompleteConfidence
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift®, and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Rx only Contraindication: The
Arrowg+ard Blue Plus® CVC is contraindicated for patients with
known hypersensitivity to chlorhexidine and silver sulfadiazine
and/or sulfa drugs.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus,
Deknatel, ErgoPack, GlideWheel, Hudson RCI, LMA, Pilling, Rusch,
UroLift, and Weck are trademarks or registered trademarks of
Teleflex Incorporated or its affiliates, in the U.S. and/or other
countries. All other marks are the property of their respective
owners.© 2020 Teleflex Incorporated. All rights reserved.
MC-006733
References:
- 1. Raad, II,
Hohn DC, Gilbreath BJ, et al. Prevention of central venous
catheter-related infections by using maximal sterile barrier
precautions during insertion. Infection Control and Hospital
Epidemiology. 1994;15(4 Pt 1): 231-238.
- DRG data. Teleflex. 2020.
-
https://www.ahrq.gov/topics/central-line-associated-bloodstream-infections-clabsi.html
- O’Grady NP, Alexander M, Burns LA,
et al. Guidelines for the Prevention of Intravascular
Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA:
Centers for Disease Control and Prevention; 2017.
- Marschall J, Mermel LA, Fakih M, et
al. Strategies to Prevent Central Line–Associated Bloodstream
Infections in Acute Care Hospitals: 2014 Update. Infection Control
and Hospital Epidemiology. 2014 July; 35(7): 753-71.
- Gorski L, Hadaway L, Hagle ME,
McGoldrick M, et al. Infusion Therapy Standards of Practice.
Journal of Infusion Nursing. 2016; Jan 39(1S).
- Occupational Safety & Health
Administration Regulations (Standards – 29 CFR). Part 1910.1030:
Bloodborne pathogens. Occupational Safety & Health
Administration Web site.
https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030.
Accessed on February 12, 2020.
Source: Teleflex IncorporatedJake
ElguiczeTreasurer and Vice President, Investor
Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2024 to May 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From May 2023 to May 2024